scholarly journals Hypoxic Incubation Conditions for Optimized Manufacture of Tenocyte-Based Active Pharmaceutical Ingredients of Homologous Standardized Transplant Products in Tendon Regenerative Medicine

Cells ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 2872
Author(s):  
Annick Jeannerat ◽  
Cédric Peneveyre ◽  
Florence Armand ◽  
Diego Chiappe ◽  
Romain Hamelin ◽  
...  
Keyword(s):  
Regenerative Medicine ◽  
Cell Surface ◽  
Size Distribution ◽  
Matrix Protein ◽  
Surface Marker ◽  
Cell Surface Marker ◽  
Active Pharmaceutical Ingredients ◽  
Cell Size Distribution ◽  
Pharmaceutical Ingredients ◽  
Hypoxic Incubation

Human fetal progenitor tenocytes (hFPT) produced in defined cell bank systems have recently been characterized and qualified as potential therapeutic cell sources in tendon regenerative medicine. In view of further developing the manufacture processes of such cell-based active pharmaceutical ingredients (API), the effects of hypoxic in vitro culture expansion on key cellular characteristics or process parameters were evaluated. To this end, multiple aspects were comparatively assessed in normoxic incubation (i.e., 5% CO2 and 21% O2, standard conditions) or in hypoxic incubation (i.e., 5% CO2 and 2% O2, optimized conditions). Experimentally investigated parameters and endpoints included cellular proliferation, cellular morphology and size distribution, cell surface marker panels, cell susceptibility toward adipogenic and osteogenic induction, while relative protein expression levels were analyzed by quantitative mass spectrometry. The results outlined conserved critical cellular characteristics (i.e., cell surface marker panels, cellular phenotype under chemical induction) and modified key cellular parameters (i.e., cell size distribution, endpoint cell yields, matrix protein contents) potentially procuring tangible benefits for next-generation cell manufacturing workflows. Specific proteomic analyses further shed some light on the cellular effects of hypoxia, potentially orienting further hFPT processing for cell-based, cell-free API manufacture. Overall, this study indicated that hypoxic incubation impacts specific hFPT key properties while preserving critical quality attributes (i.e., as compared to normoxic incubation), enabling efficient manufacture of tenocyte-based APIs for homologous standardized transplant products.

scholarly journals Isolation of Neural Progenitor Cells From the Human Adult Subventricular Zone Based on Expression of the Cell Surface Marker CD271

2014 ◽  
Vol 3 (4) ◽  
pp. 470-480 ◽  
Author(s):  
Miriam E. van Strien ◽  
Jacqueline A. Sluijs ◽  
Brent A. Reynolds ◽  
Dennis A. Steindler ◽  
Eleonora Aronica ◽  
...  
Keyword(s):  
Cell Surface ◽  
Progenitor Cells ◽  
Subventricular Zone ◽  
Neural Progenitor Cells ◽  
Neural Progenitor ◽  
Surface Marker ◽  
Cell Surface Marker ◽  
Human Adult

scholarly journals Epha1 is a cell surface marker for neuromesodermal progenitors and their early mesoderm derivatives

2019 ◽  
Author(s):  
Luisa de Lemos ◽  
André Dias ◽  
Ana Nóvoa ◽  
Moisés Mallo
Keyword(s):  
Cell Surface ◽  
Transcriptional Profiling ◽  
Surface Marker ◽  
Cell Surface Marker ◽  
Paraxial Mesoderm ◽  
Molecular Signature ◽  
Tail Bud ◽  
Molecular Fingerprint ◽  
Simple Method ◽  
Cell Subpopulations

ABSTRACTThe vertebrate body is built during embryonic development by the sequential addition of new tissue as the embryo grows at its caudal end. During this process, the neuro-mesodermal progenitors (NMPs) generate the postcranial neural tube and paraxial mesoderm. Recently, several approaches have been designed to determine their molecular fingerprint but a simple method to isolate NMPs from embryos without the need for transgenic markers is still missing. We isolated NMPs using a genetic strategy that exploits their self-renew properties, and searched their transcriptome for cell surface markers. We found a distinct Epha1 expression profile in progenitor-containing areas of the mouse embryo, consisting of two cell subpopulations with different Epha1 expression levels. We show that Sox2+/T+ cells are preferentially associated with the Epha1 compartment, indicating that NMPs might be contained within this cell pool. Transcriptional profiling showed enrichment of high Epha1-expressing cells in known NMP and early mesoderm markers. Also, tail bud cells with lower Epha1 levels contained a molecular signature suggesting the presence of notochord progenitors. Our results thus indicate that Epha1 could represent a valuable cell surface marker for different subsets of axial progenitors, most particularly for NMPs taking mesodermal fates.

scholarly journals Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine

Cells ◽  
2021 ◽  
Vol 10 (10) ◽  
pp. 2526
Author(s):  
Alexis Laurent ◽  
Philippe Abdel-Sayed ◽  
Nathalie Hirt-Burri ◽  
Corinne Scaletta ◽  
Murielle Michetti ◽  
...  
Keyword(s):  
Regenerative Medicine ◽  
Respiratory Tract ◽  
Lung Tissue ◽  
Cell Types ◽  
Active Pharmaceutical Ingredients ◽  
Vaccine Production ◽  
Diploid Progenitor ◽  
Pharmaceutical Ingredients ◽  
The 1960S ◽  
Pharmacopoeial Requirements

The objective of this review is to describe the evolution of lung tissue-derived diploid progenitor cell applications, ranging from historical biotechnological substrate functions for vaccine production and testing to current investigations around potential therapeutic use in respiratory tract regenerative medicine. Such cell types (e.g., MRC-5 or WI-38 sources) were extensively studied since the 1960s and have been continuously used over five decades as safe and sustainable industrial vaccine substrates. Recent research and development efforts around diploid progenitor lung cells (e.g., FE002-Lu or Walvax-2 sources) consist in qualification for potential use as optimal and renewed vaccine production substrates and, alternatively, for potential therapeutic applications in respiratory tract regenerative medicine. Potentially effective, safe, and sustainable cell therapy approaches for the management of inflammatory lung diseases or affections and related symptoms (e.g., COVID-19 patients and burn patient severe inhalation syndrome) using local homologous allogeneic cell-based or cell-derived product administrations are considered. Overall, lung tissue-derived progenitor cells isolated and produced under good manufacturing practices (GMP) may be used with high versatility. They can either act as key industrial platforms optimally conforming to specific pharmacopoeial requirements or as active pharmaceutical ingredients (API) for potentially effective promotion of lung tissue repair or regeneration.

Sign in / Sign up

Export Citation Format

Share Document